Dr. Kipp specializes in the diagnosis and treatment of neuroimmunological disorders, particularly demyelinating conditions such as multiple sclerosis and neuromyelitis optica. He is interested in translational research connecting expert MS clinicians, world-renown immunology laboratories, and advanced neuroimaging techniques to identify biomarkers of disease and treatment response.

Clinical Focus

  • Neurology

Academic Appointments

Administrative Appointments

  • Director, MS/Clinical Neuroimmunology Fellowship Program (2016 - Present)

Honors & Awards

  • MS Clinical Fellowship Award, Canadian Network of Multiple Sclerosis Clinics (2014)

Boards, Advisory Committees, Professional Organizations

  • Fellow, Royal College of Physicians and Surgeons of Canada (2014 - Present)
  • Member, American Academy of Neurology (2008 - Present)
  • Member, National Consortium of MS Clinics (2016 - Present)

Professional Education

  • Fellowship:Stanford University Neuroimmunology and Multiple Sclerosis FellowshipCA
  • Fellowship:University College London Institute of Neurology (2015) United Kingdom
  • Residency:University of British Columbia Dept of Neurology (2014) Canada
  • Clinical Fellowship, Stanford University School of Medicine, CA, MS/Neuroimmunology (2016)
  • Board Certification: Neurology, Royal College of Physicians and Surgeons of Canada (2014)
  • Research Fellowship, University College London, London, UK, MS Advanced Neuroimaging (2015)
  • Neurology Residency, University of British Columbia, Vancouver, Canada (2014)
  • Medical Education:University of Western Ontario (2009) Canada
  • Doctor of Medicine (MD), University of Western Ontario, London, Canada (2009)
  • Bachelor of Science (BSc), University of Western Ontario, London, Canada (2005)


All Publications

  • Coexistence of Neuromyelitis Optica and Amyotrophic Lateral Sclerosis: A Case Report NEUROHOSPITALIST Li, A., McGranahan, T., Su, E., Kipp, L., Gold, C. A. 2019; 9 (1): 37–40
  • Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab Carlson, A., Bozinov, N., Kipp, L., Dunn, J., Lock, C. LIPPINCOTT WILLIAMS & WILKINS. 2018
  • Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES Sadovnick, A. D., Yee, I. M., Attwell-Pope, K., Keyes, G., Kipp, L., Traboulsee, A. L. 2017; 44 (3): 246-254


    Objective Chronic cerebrospinal venous insufficiency (CCSVI) has been hypothesized to be a risk factor for multiple sclerosis (MS). Venoplasty has been proposed as a treatment for CCSVI. The aim of our study was to gain a better understanding of the "real-world" safety and longitudinal effectiveness of venoplasty Methods: British Columbia residents who self-reported having had venoplasty and consented to participate in the study were interviewed and followed for up to 24 months post-therapy using standardized structured questionnaires Results: Participants reported procedure-related complications (11.5%) and complications within the first month after the procedure (17.3%). Initially, more than 40% of participants perceived that the venoplasty had had positive effects on their health conditions, such as fatigue, numbness, balance, concentration/memory and mobility. However, this improvement was not maintained over time Conclusions: Follow-up patient-reported outcomes indicated that the initial perception of the positive impact of venoplasty on the health conditions of MS patients was not sustained over time. In addition, venoplasty was not without associated morbidity.

    View details for DOI 10.1017/cjn.2017.27

    View details for Web of Science ID 000401287500003

    View details for PubMedID 28270250